Dr Reddys Laboratories (RDY) EBITDA Margin (2009 - 2023)

Dr Reddys Laboratories (RDY) has reported EBITDA Margin for 15 consecutive years, with 25.97% the latest figure, recorded in Q2 2023.

• Quarterly EBITDA Margin changed N/A year-over-year to 25.97% in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 24.27% (changed N/A YoY) and the FY2026 annual result came in at 15.06%, down 704.0% from the prior year.
• EBITDA Margin retreated to 25.97% in Q2 2023 per RDY's latest filing, from 32.06% in the prior quarter.
• Over the last five years, EBITDA Margin for RDY reached as high as 32.06% in Q1 2023 and fell as low as 13.36% in Q3 2019.
• A 5-year average of 15.72% and a median of 19.45% in 2019 frame the typical range for EBITDA Margin.
• The largest YoY upside for EBITDA Margin was 772 bps in 2019 against a maximum downside of 2826 bps in 2019.
• Year by year, EBITDA Margin stood at 13.36% in 2019, then grew by 11 bps to 11.85% in 2020, then soared by 277 bps to 20.98% in 2021, then grew by 24 bps to 25.95% in 2022, then advanced by 0 bps to 25.97% in 2023.
• According to Business Quant data, EBITDA Margin over the past three periods registered 25.97%, 32.06%, and 25.95% for Q2 2023, Q1 2023, and Q4 2022 respectively.